Small reduction in lung function with Tx de-escalation in COPD
(HealthDay)—A de-escalation from triple therapy to indacaterol/glycopyrronium may lead to a small reduction in lung function in non-frequently exacerbating patients with chronic obstructive pulmonary disease (COPD) but no difference in exacerbations, according to a study published in the Aug. 1 issue of the American Journal of Respiratory and Critical Care Medicine.
Kenneth R. Chapman, M.D., from the University of Toronto, and colleagues conducted a 26-week randomized trial to examine the direct change from long-term triple therapy (tiotropium, salmeterol, fluticasone propionate) to indacaterol/glycopyrronium or continuation of triple therapy in non-frequently exacerbating patients with moderate-to-severe COPD. A total of 527 and 526 patients were randomized to indacaterol/glycopyrronium and triple therapy, respectively.
The researchers found that there was a reduction in trough forced expiratory volume in one second of −26 ml (95 percent confidence interval, −53 to 1 ml) with inhaled corticosteroids withdrawal, with confidence intervals exceeding the non-inferiority margin of −50 ml. Between treatments, there was no difference in the annualized rate of moderate or severe COPD exacerbations (rate ratio, 1.08; 95 percent confidence interval, 0.83 to 1.4). Lung function loss was greater and exacerbation risk higher for patients with ≥300 blood eosinophils/µl at baseline. The two groups had similar adverse events.
"The higher exacerbation risk in patients with ≥300 blood eosinophils/µl suggests that these patients are likely to benefit from triple therapy," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Novartis Pharma, which funded the study.
Editorial (subscription or payment may be required)
Copyright © 2018 HealthDay. All rights reserved.